Aadi Bioscience (NASDAQ:AADI) Stock Price Down 16.1% – Should You Sell?

Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) were down 16.1% during trading on Monday . The stock traded as low as $3.00 and last traded at $3.02. Approximately 441,737 shares traded hands during mid-day trading, an increase of 8% from the average daily volume of 410,748 shares. The stock had previously closed at $3.60.

Aadi Bioscience Trading Up 8.4 %

The company’s 50 day moving average price is $2.65 and its 200 day moving average price is $2.05. The company has a market cap of $79.86 million, a price-to-earnings ratio of -1.42 and a beta of 0.65.

Aadi Bioscience (NASDAQ:AADI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.46) EPS for the quarter, meeting analysts’ consensus estimates of ($0.46). Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. The firm had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.55 million. During the same quarter last year, the firm earned ($0.60) earnings per share. Sell-side analysts predict that Aadi Bioscience, Inc. will post -1.78 earnings per share for the current year.

Institutional Trading of Aadi Bioscience

A number of institutional investors have recently modified their holdings of the business. BML Capital Management LLC purchased a new position in Aadi Bioscience in the third quarter worth $4,120,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Aadi Bioscience during the 2nd quarter worth $37,000. Finally, XTX Topco Ltd purchased a new position in shares of Aadi Bioscience in the 3rd quarter valued at about $32,000. 52.08% of the stock is currently owned by hedge funds and other institutional investors.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.